CytomX Therapeutics
CTMX
84 hedge funds and large institutions have $52.6M invested in CytomX Therapeutics in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 23 increasing their positions, 24 reducing their positions, and 25 closing their positions.
4% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 24
14% less funds holding
Funds holding: 98 → 84 (-14)
14.62% less ownership
Funds ownership: 69.65% → 55.03% (-15%)
56% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 25
62% less capital inflows, than outflows
Capital inflows: $11M | Capital outflows: $29.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Tang Capital Management
San Diego,
California
|
+$3.76M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$1.64M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.25M |
| 4 |
BVF Inc
San Francisco,
California
|
+$1.22M |
| 5 |
Renaissance Technologies
New York
|
+$541K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RTW Investments
New York
|
-$5.22M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.03M |
| 3 |
OrbiMed
New York
|
-$3.89M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.66M |
| 5 |
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$3.03M |
CTMX Hedge Fund Activity: Q3 2022 in Review
84 of the 5,832 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q3 2022, worth a combined $52.6M — down 37% from $83.4M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of CTMX and 11 opened new positions — a net loss of 14 holders — while 24 trimmed existing stakes and 23 added.
The largest buyer was Tang Capital Management, adding an estimated $3.76M. The largest seller was RTW Investments, exiting entirely with an estimated $5.22M sold.
- 84 institutional investors held CytomX Therapeutics (CTMX) as of Q3 2022, down from 98 in Q2 2022.
- Funds reported $52.6M of CytomX Therapeutics stock for Q3 2022, down 37% quarter-over-quarter.
- 11 funds opened new CytomX Therapeutics positions in Q3 2022 and 25 closed out, a net change of -14 holders.
- The largest CytomX Therapeutics buyer in Q3 2022 was Tang Capital Management, an estimated $3.76M added.
- The largest CytomX Therapeutics seller in Q3 2022 was RTW Investments, an estimated $5.22M sold.
Based on aggregated 13F filings for Q3 2022.